BioSpace News Archive

Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the fourth quarter and full year ended December 31, 2022 after the market close on Tuesday, February 21, 2023.

Freeline Therapeutics Holdings plc announced that on January 31, 2023, the Company granted two newly hired employees non-statutory options to purchase an aggregate of 81,000 of the Company’s ordinary shares.

Amarin Corporation plc announced that it has mailed a letter to shareholders in connection with the General Meeting of Shareholders urging shareholders to vote “AGAINST” all proposals on the WHITE proxy card.

PTC Therapeutics, Inc. announced that the company will present a company overview at the following conference.

Johnson & Johnson will participate in the Cowen 43rd Annual HealthCare Conference on Tuesday, March 7th, at the Boston Marriott Copley Place, Boston, MA.

Sesen Bio, Inc. filed an investor presentation highlighting its value maximizing merger with Carisma Therapeutics Inc.

Olema Pharmaceuticals, Inc. announced that the Company granted stock options to four new employees to purchase an aggregate of 97,200 shares of the Company’s common stock, effective as of February 1, 2023.

Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and pulmonary diseases, today announced the pricing of its upsized initial public offering of 10,740,000 American depositary shares (ADSs), each representing three ordinary shares, at a public offering price of $15.00 per ADS.

Roivant Sciences (Nasdaq: ROIV) today announced the pricing of an upsized underwritten public offering of 26,666,666 of its common shares at a price to the public of $7.50 per share.

Avalo Therapeutics, Inc. (NASDAQ: AVTX) (Avalo) announced today the pricing of an underwritten public offering of 3,770,000 shares of its common stock and warrants to purchase up to an aggregate of 3,770,000 shares of common stock, at a price to the public of $3.98 per share and warrant.